非典型垂体腺瘤诊断相关的变异性和缺乏预后价值:对诊断标准的系统评价与批判性评估
该系统评价检索PubMed(2004年至2017年7月)以评估非典型垂体腺瘤(APA)的患病率和结局。7105例患者中373例(5.2%)符合APA标准(患病率范围3%-15%),仅2/8项研究使用完全相同的分级标准。APA患者复发/进展率为21%(随访范围37-75个月),仅2/8项研究报告APA诊断与复发/进展相关。作者认为既往APA命名因预后价值有限应被废弃。
要点
- 7105例垂体腺瘤患者中373例(5.2%)符合APA标准,患病率范围3%-15%。
- 仅2/8项研究使用完全相同的分级标准,APA诊断标准应用缺乏标准化。
- APA患者复发/进展率为21%(随访范围37-75个月),仅2/8项研究报告APA诊断与复发/进展相关。
核心结论
- 基于诊断变异性和缺乏与临床结局的关联,有必要完善APA标准。
- WHO更新消除了APA诊断的模糊性,转而采用强调临床行为(侵袭、复发和治疗抵抗)和分子标志物的标准。
- 该系统评价支持废弃既往APA命名,因其预后价值有限。
研究设计与样本
- 系统评价PubMed(2004年至2017年7月)以识别报告APA患病率和临床特征/结局的研究。
- 8项研究纳入患病率分析,6项报告组织病理学细节的研究进行深入分析。
主要发现
- 7105例纳入患者中373例(5.2%)符合APA标准(患病率范围3%-15%)。
- 仅2/8项研究使用完全相同的分级标准,表明缺乏标准化应用。
- 大多数APA(84%)为大腺瘤,52%在磁共振成像上呈侵袭性。
- 无功能性垂体腺瘤最常见(37%),其次为泌乳素瘤(23%)和生长激素腺瘤(21%)。
- APA患者复发/进展率为21%(随访范围37-75个月),仅2/8项研究报告APA诊断与复发/进展相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atypical pituitary adenomas (APAs) are a subset of pituitary adenomas (PAs) characterized by the 2004 World Health Organization (WHO) guidelines to have higher risk histopathological features than typical PAs. In July 2017, the WHO published an update to their classification of pituitary tumors and abandoned the APA terminology. OBJECTIVE: To assess the prevalence and outcomes of patients diagnosed with APA through a literature review. Focus was placed on variation in the application of the previous WHO criteria and on rates of recurrence. METHODS: A systematic review of PubMed (2004-July 2017) was performed to identify studies reporting prevalence and clinical characteristics/outcomes of APA. Eight studies were analyzed for prevalence. Six studies reporting histopathological details were analyzed in depth. RESULTS: Of the 7105 included patients, 373 (5.2%) met criteria for APA (prevalence range: 3%-15%). Only 2 of 8 studies utilized identical grading criteria, demonstrating a lack of standardized application. Most APAs (84%) were macroadenomas, with 52% invasive on magnetic resonance imaging. Nonfunctional PAs were most common (37%), followed by prolactinomas (23%) and Growth Hormone adenomas (21%). Recurrence/progression occurred in 21% of APA patients (follow-up range 37-75 mo). Only 2 of 8 studies reported an association between APA diagnosis and recurrence/progression. CONCLUSION: Based on diagnostic variability and lack of association with clinical outcomes, refinement of criteria for APA was necessary. The WHO update eliminates the ambiguity in APA diagnosis in favor of criteria that emphasize clinical behavior (invasion, recurrence, and resistance to treatment) and molecular markers. Our review supports abandonment of the previous APA designation due to limited prognostic utility.
引用
- Chesney K, Memel Z, Pangal DJ, et al. Variability and Lack of Prognostic Value Associated With Atypical Pituitary Adenoma Diagnosis: A Systematic Review and Critical Assessment of the Diagnostic Criteria. Neurosurgery. 2018. PMID: 29165661. doi:10.1093/neuros/nyx541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。